ES2104697T3 - Formulados farmaceuticos. - Google Patents

Formulados farmaceuticos.

Info

Publication number
ES2104697T3
ES2104697T3 ES91907052T ES91907052T ES2104697T3 ES 2104697 T3 ES2104697 T3 ES 2104697T3 ES 91907052 T ES91907052 T ES 91907052T ES 91907052 T ES91907052 T ES 91907052T ES 2104697 T3 ES2104697 T3 ES 2104697T3
Authority
ES
Spain
Prior art keywords
pharmaceutical
formulates
alfaglycerol
formulation
biologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907052T
Other languages
English (en)
Inventor
Young W Cho
Michael John Flynn
Thomas Smith Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skua Investments Ltd
Original Assignee
Skua Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10673486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2104697(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Skua Investments Ltd filed Critical Skua Investments Ltd
Application granted granted Critical
Publication of ES2104697T3 publication Critical patent/ES2104697T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTA UNA FORMULACION FARMACEUTICA QUE COMPRENDE UN MATERIAL BIOLOGICAMENTE ACTIVO TAL COMO INSULINA, ERITROPOIETINA, CALCITONINA Y HORMONA DE CRECIMIENTO, Y, ASOCIADO CON ELLOS, UN FOSFOLIPIDO PARA FORMAR UN MATERIAL QUE SE PRECIPITA EN ALFAGLICEROL PARA LA FORMACION DE LECITINAS QUE SE HAN ENCONTRADO EN LAS CELULAS HEPITELIALES INTESTINALES. LAS PROTEINAS BIOLOGICAMENTE ACTIVAS ADMINISTRADAS ORALMENTE DE ESTA FORMULACION SE ENCUENTRAN BIODISPONIBLES Y SON BIOACTIVAS.
ES91907052T 1990-03-29 1991-04-02 Formulados farmaceuticos. Expired - Lifetime ES2104697T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909007052A GB9007052D0 (en) 1990-03-29 1990-03-29 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ES2104697T3 true ES2104697T3 (es) 1997-10-16

Family

ID=10673486

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907052T Expired - Lifetime ES2104697T3 (es) 1990-03-29 1991-04-02 Formulados farmaceuticos.

Country Status (24)

Country Link
US (1) US5665700A (es)
EP (1) EP0521994B1 (es)
JP (1) JPH05505192A (es)
KR (1) KR100197915B1 (es)
AT (1) ATE154515T1 (es)
AU (1) AU656134B2 (es)
CA (1) CA2079233A1 (es)
CS (1) CS88091A2 (es)
DE (1) DE69126609T2 (es)
DK (1) DK0521994T3 (es)
ES (1) ES2104697T3 (es)
FI (1) FI101043B (es)
GB (1) GB9007052D0 (es)
GR (1) GR3024745T3 (es)
HK (1) HK1004531A1 (es)
HU (2) HUT63341A (es)
IE (1) IE911086A1 (es)
NO (1) NO923768D0 (es)
NZ (1) NZ237667A (es)
PT (1) PT97199B (es)
RU (1) RU2104715C1 (es)
SG (1) SG54998A1 (es)
WO (1) WO1991014454A1 (es)
ZA (1) ZA912411B (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
EP0566135A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
US6916489B2 (en) * 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
DK0955062T3 (da) * 1992-07-31 2007-09-17 Genentech Inc Vandig formulering indeholdende humant væksthormon
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US20010003001A1 (en) * 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ATE180423T1 (de) * 1993-09-29 1999-06-15 Technobiochip Duenne proteinschichten und zusammensetzungen zu ihrer herstellung
CA2175494C (en) * 1993-11-03 2000-09-19 Young W. Cho Microparticular pharmaceutical compositions
EP0788346B9 (en) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulsified drug delivery systems
US5851510A (en) * 1994-05-16 1998-12-22 The Board Of Regents Of The University Of Michigan Hepatocyte-selective oil-in-water emulsion
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
GB9424902D0 (en) * 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
CN1151836C (zh) 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
GB2320248B (en) 1995-09-11 1999-04-14 Emisphere Tech Inc Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
IL126318A (en) 1996-03-29 2004-09-27 Emisphere Tech Inc Compounds and compositions for delivering active agents and some novel carrier compounds
US6063370A (en) * 1996-04-05 2000-05-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
CA2258264A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
DE19724845A1 (de) * 1996-08-28 1998-03-05 Solvay Pharm Gmbh Verwendung von komplexen Lipiden als stabilisierende Zusätze zu pharmazeutischen Zubereitungen von Verdauungsenzymgemischen
GB9625589D0 (en) 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804688A (en) 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5830432A (en) * 1997-03-31 1998-11-03 Amur Pharmacuticals, Inc. Phospholipid drug derivatives
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
SE9801287D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
US7498310B1 (en) 1998-08-13 2009-03-03 Beiersdorf Ag Cosmetic or dermatological preparations comprising oligopeptides for lightening the skin of age marks and/or for preventing tanning of the skin, in particular tanning of the skin caused by UV radiation
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6350432B1 (en) 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
WO2000056291A1 (en) * 1999-03-19 2000-09-28 Generex Pharmaceuticals Inc. Pharmaceutical solubilized in aerosol propellant
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
CA2369444C (en) * 1999-04-09 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical compositions of erythropoietin
US7556827B1 (en) * 1999-08-06 2009-07-07 Max-Delbrück-Centrum-für Molekulare Medizin Implantable active ingredient depot
CA2381713A1 (en) * 1999-09-02 2001-03-08 Big Bear Bio, Inc. Methods and compositions for reducing serum phosphate levels
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
RU2155602C1 (ru) * 1999-11-30 2000-09-10 Оао "Куантум Сатис" Инсулинсодержащее лекарственное средство для перорального применения и способ его получения
ES2298168T3 (es) * 1999-12-16 2008-05-16 Emisphere Technologies, Inc. Compuestos y composiciones para suministrar agentes activos.
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
AU783952B2 (en) * 2000-02-04 2006-01-05 Unigene Laboratories, Inc. Nasal calcitonin formulations
US6417237B1 (en) 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
US8658202B2 (en) 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
WO2003009704A2 (en) * 2001-07-27 2003-02-06 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
US6951655B2 (en) * 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
AU2003253687A1 (en) * 2002-10-09 2004-05-04 The Azza Co., Ltd. Liposomal hgh composition and method for administration thereof
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US8211448B2 (en) * 2003-07-07 2012-07-03 Nares Ab Microemulsions and its use for preventing airway diseases
JP2005209106A (ja) * 2004-01-26 2005-08-04 Nec Corp 携帯通信端末、受信メール管理方法、プログラムおよび記録媒体
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
US8449867B2 (en) 2004-08-31 2013-05-28 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
AU2005279704B2 (en) * 2004-08-31 2010-05-13 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
EP1652513A1 (en) * 2004-11-02 2006-05-03 Denderah Pharm Sa Reverse micelles based on sterols and acylglycerols and therapeutic uses thereof
GB0428515D0 (en) * 2004-12-30 2005-02-09 Unilever Plc Edible compositions and their preparation
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
WO2007029238A2 (en) 2005-09-06 2007-03-15 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
DE102006056783A1 (de) * 2006-12-01 2008-06-05 Lts Lohmann Therapie-Systeme Ag Zubereitung zur transdermalen Verabreichung von Galanthamin
RU2411039C2 (ru) * 2007-12-26 2011-02-10 Валентина Васильевна Малиновская Иммунокорригирующее средство для лечения заболеваний вирусной этиологии
RU2367472C1 (ru) * 2008-03-17 2009-09-20 Общество С Ограниченной Ответственностью "Технология Лекарств" Парентеральное лекарственное средство и способ его получения
NZ588603A (en) 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
US20110046053A1 (en) 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
WO2010050918A1 (en) * 2008-10-31 2010-05-06 Qinghai Zhang Branched chain detergents for membrane protein structural biology
US20140154377A1 (en) * 2011-04-04 2014-06-05 Dsm Ip Assets B.V. Oil-in-water emulsions comprising a polyunsaturated fatty acid and methods of making the same
EP3260131A1 (en) 2012-01-03 2017-12-27 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
CN113769074A (zh) 2012-02-01 2021-12-10 奥拉姆德有限公司 含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法
WO2014106846A2 (en) 2013-01-03 2014-07-10 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
EP3820455B1 (en) * 2018-07-10 2024-06-19 Universidade de Santiago de Compostela Nanostructure lipid system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1180996A (en) * 1967-08-30 1970-02-11 Inst Rech S Chimiques Et Biolo Solubilised Cytochrome C-phospholipid Complexes
US4164573A (en) * 1975-06-13 1979-08-14 Galinsky Alvin M Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
JPS5517328A (en) * 1978-07-21 1980-02-06 Tanabe Seiyaku Co Ltd Insulin-containing emulsion and its preparation
JPS5770814A (en) * 1980-10-17 1982-05-01 Isamu Horikoshi Oral preparation of blood clotting eighth factor
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
JPS6058915A (ja) * 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
FR2581543B1 (fr) * 1985-05-09 1989-07-07 Tressens Dominique Pharmacotechnie permettant la realisation d'une preparation insulinique active par voie orale
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
DE3750369T2 (de) * 1986-03-21 1995-05-24 Eurasiam Lab Arzneimittelzusammensetzungen.
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation

Also Published As

Publication number Publication date
AU7584291A (en) 1991-10-21
FI924340A0 (fi) 1992-09-28
NO923768L (no) 1992-09-28
CS88091A2 (en) 1991-11-12
FI924340L (fi) 1992-09-28
US5665700A (en) 1997-09-09
RU2104715C1 (ru) 1998-02-20
SG54998A1 (en) 1998-12-21
EP0521994A1 (en) 1993-01-13
PT97199B (pt) 1998-07-31
IE911086A1 (en) 1991-10-09
NZ237667A (en) 1994-01-26
ZA912411B (en) 1992-11-25
AU656134B2 (en) 1995-01-27
GB9007052D0 (en) 1990-05-30
NO923768D0 (no) 1992-09-28
JPH05505192A (ja) 1993-08-05
PT97199A (pt) 1991-11-29
HK1004531A1 (en) 1998-11-27
HUT63341A (en) 1993-08-30
HU9203093D0 (en) 1992-12-28
DE69126609D1 (de) 1997-07-24
KR100197915B1 (ko) 1999-06-15
FI101043B (fi) 1998-04-15
HU211962A9 (en) 1996-01-29
DK0521994T3 (da) 1997-07-07
WO1991014454A1 (en) 1991-10-03
CA2079233A1 (en) 1991-09-30
GR3024745T3 (en) 1997-12-31
DE69126609T2 (de) 1998-01-02
ATE154515T1 (de) 1997-07-15
EP0521994B1 (en) 1997-06-18

Similar Documents

Publication Publication Date Title
ES2104697T3 (es) Formulados farmaceuticos.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
ES2007607A6 (es) Un procedimiento para la obtencion de un preparado de insulina para la administracion no parenteral.
ES2081384T3 (es) Preparado farmaceutico que contiene complejos de polielectrolitos en forma de microparticulas y por lo menos una sustancia activa.
ES2181723T3 (es) Formulaciones farmaceuticas de factor de crecimiento nervioso.
ES2043897T3 (es) Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
ES2003064A4 (es) Metodos de diagnostico para detectar linfomas en el hombre.
ES489204A1 (es) Elemento destinado a implantarse en tejido corporal, parti- cularmente tejido oseo
ATE196248T1 (de) Vesikel mit gesteuerter wirkstofffreisetzung
MX9201782A (es) Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
DE69221484D1 (de) Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
BR9610929A (pt) Processos para liberar um ou mais polipeptídeos biologicamente ativos, e um ou mais antígenos, para regular as funções de sobrevivência, crescimento, diferenciação, efetuadora ou suscetibilidade a infeção de células ou tecidos, para refoçar uma resposta imune contra células de tumor ou uma infecção colonizado uma superfície mucosal ou tecido distante ou adjacente, para modular o tipo de resposta imune ( anticorpo versus mediada por célula) contra um agente infeccioso patogênico, para induzir a apoptose em células
ES2183841T3 (es) Formas de dosificacion para administrar un farmasco en una formulacion lquidid.
ES2170259T3 (es) Empleo de lipidos como agentes auxiliares en la obtencion de formas farmaceuticas solidas segun el procedimiento de extrusion en fusion.
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
DE69025927D1 (de) Zusammensetzung und behandlung mit biologisch aktiven peptiden und antibiotika
DE59706445D1 (de) Verfahren zur herstellung eines implantates, bestehend aus einem resorbierbaren trägermaterial, eine medizinische wirksubstanz wie ein pharmazeutika, antibiotika, cytostatika oder hormon enthaltend
DE3763851D1 (de) System zur arzneistoffabgabe mit erhoehter bioakzeptanz.
ATE113470T1 (de) Gehirnspezifische zubereitung mit gesteuerter abgabe.
MX9301535A (es) Material proteinaceo biologicamente activo aislado y purificado.
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
ES2157900T3 (es) Nuevos conjugados de proteinas y policationes.
NO932236D0 (no) Farmasoeytisk preparat inneholdende probukol med forhoeyet biotilgjengelighet
ES2169089T3 (es) Producto de plantas para controlar las respuestas inmunes en mamiferos y procedimiento para fabricar dicho producto.
ES2118726T3 (es) Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 521994

Country of ref document: ES